FAME                                                  gastric(61)
 _________________________________________________________________
  fluorouracil.... 350 mg/sqm/day IV on days 1 to 5; 

                   and on days 36 to 40.
  adriamycin...... 40 mg/sqm IV on days 1 and 36.
  semustine....... 150 mg/sqm orally on day 1.
  FREQUENCY....... Repeat cycle every 10 weeks.

  reference...
    Anonymous. Phase II-III chemotherapy studies in advanced 
    gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 
    Treatment Reports.  63(11-12):1871-6, 1979 Nov-Dec. 
  abstract...
      In this multi-institutional study of advanced gastric 
    cancer, 141 eligible and evaluable patients were treated with 
    either (a) Adriamycin alone, (b) a combination of 
    5-fluorouracil, Adriamycin, and methyl-CCNU (FAMe), or (c) a 
    combination of 5-fluorouracil, mitomycin C, and cytosine 
    arabinoside (FMC). In patients with measurable disease and no 
    prior chemotherapy, objective responses were seen in four of 
    17 patients (24%) receiving Adriamycin alone, in seven of 15 
    (47%) receiving FAMe, and in three of 18 (17%) receiving FMC. 
    In previously treated patients with measurable disease, 
    objective responses were seen in three of 17 patients (18%) 
    receiving Adriamycin alone and in one of 11 (9%) receiving 
    FMC. In previously untreated patients with both measurable and 
    nonmeasurable disease, FAMe showed a significant advantage 
    over both Adriamycin alone and FMC with regard to interval to 
    disease progression and survival. In comparing Adriamycin 
    alone with FMC in previously treated patients, intervals to 
    disease progression and survival were essentially identical.